close
Enquiry IconContact Us
Logo

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Ataxia is a group of degenerative disorders associated with the cerebellum in the brain, which is responsible for regulating balance and coordination of the body. Ataxia does not have a cure and only its symptoms such as weakness, difficulty in movement and others can be treated. Ataxia can be of several types such as spinocerebellar ataxia, Friedreich’s ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and others.

Spinocerebellar ataxia (SCA) is caused due to genetic defects, which lead to impairment of nerve fibers carrying neural signals in the brain, thus resulting in degeneration of cerebellum. People with this condition tend to face difficulties in movement and balance, develop weakness in body, difficulty in eye movement, and others. SCA is a progressive type of ataxia and can occur at any age. Friedreich’s ataxia is a type of genetic ataxia wherein in addition to common movement related symptoms, people also experience stiffness and loss of sensation in muscles, weakness in the body, heart condition (hypertrophic cardiomyopathy), and others.

Ataxia-telangiectasia, also known as louis-bar syndrome is a genetic ataxia, which is seen mostly in new born babies and young children. Some of the characteristic symptoms of ataxia-telangiectasia include appearance of enlarged blood vessels in the eyes and on the facial skin. Multiple system atrophy is an acquired type of ataxia and is a form of Parkinsonism, which affects the cerebellum and autonomic nervous system (ANS). ANS is responsible for controlling involuntary functions in the body such as blood pressure, urination, and others. Common symptoms associated with multiple system atrophy include erectile dysfunction, rapid blood pressure drop when a person stands up, difficulty coordinating movements, and others. MSA usually develops in adults of age 30 and above. Episodic ataxia is a genetic ataxia characterized by recurring troubles with movement and balance which can happen multiple times a day or just once or twice a year.

The global ataxia market is estimated to be valued at US$ 30,880.5 million in 2021 and is expected to exhibit a CAGR of 9.4% over the forecast period (2021-2028).

Figure 1. Global Ataxia Market Share (%), By Region, 2021

Ataxia  | Coherent Market Insights

The increasing incidence of ataxia is expected to drive the growth of the global ataxia market over the forecast period.

For instance, according to an article published in the Journal of Neurology, in October 2018, the global prevalence of spinocerebellar ataxia (SCA) is estimated to three 3 in 100,000 people as of 2018, wherein SCA3 subtype of spinocerebellar ataxia was found to be the most common type around the globe. The same source also stated that SCA6 subtype of spinocerebellar ataxia is one of the most common autosomal dominant cerebellar ataxia in the North of England, with a global prevalence of 5.2 per 100,000 persons.

request-sample

Ataxia Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 30,880.5 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 9.4% 2028 Value Projection: US$ 47,360.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, Others (Adaptive Devices and Occupational Therapy)
  • By Disease Type: Friedreich's Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxia, Episodic Ataxia, Others (Multiple System Atrophy (MSA))
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan

Growth Drivers:
  • Increasing prevalence of ataxia 
  • Increasing research and development in pharmaceutical industry
Restraints & Challenges:
  • Insufficient clinical trial participants due to rarity of ataxia diseases

Figure 2. Global Ataxia Market Share (%), By Treatment Type, 2021

Ataxia  | Coherent Market Insights

The increasing research and development activities for the development of novel therapeutics for the treatment of ataxia is expected to drive the market growth over the forecast period.

Key players operating in the market are focusing on submitting application for approval of drugs therapy for the treatment of ataxia, which is expected to drive growth of the global ataxia market over the forecast period.

For instance, in March 2019, Biohaven Pharmaceuticals, a U.S. based clinical stage biopharmaceutical company initiated its Phase III clinical trial of its third-generation prodrug troriluzole indicated for the treatment of spinocerebellar ataxia.

Moreover, according to an article published in the Neurobiology of Disease journal, in January 2021, an oral drug called leriglitazone has shown benefits in treating Friedrich's ataxia in cellular and animal models. Leriglitazone is manufactured by Minoryx Therapeutics, a Spain based clinical stage Biotechnology Company and is currently in advanced Phase II clinical trials for treatment of Friedrich's ataxia.

Global Ataxia Market – Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 234,553,539 cases and 4,796,222 deaths due to coronavirus (COVID-19) were reported till October 3, 2021, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. However, COVID-19 pandemic is expected to have a positive impact on the global ataxia market as recent research studies have established a link between ataxia and COVID-19 infection. For instance, according to an article published by the BMC (biomedcentral) Infectious Diseases journal in March 2021, SARS-CoV-2 infection can be a  potential cause of post-infectious neurological diseases such as ataxia, thus high-dose corticosteroid treatment must be considered if a post-infectious immune-mediated mechanism is suspected in a COVID-19 positive patient.

Global Ataxia Market Restraint

The rarity of ataxia disease is the major hurdle in conducting clinical trials for its treatment and this is expected to hinder growth of the global ataxia market over the forecast period. For instance, according to an article published by the Annals of Clinical and Translational Neurology journal, in May 2021, the rarity of spinocerebellar ataxia (SCA) is the biggest challenge faced while conducting clinical trials for treatment of SCA as there are insufficient number of people suffering from SCA which could be recruited for a given clinical trial.

Key Players      

Major players operating in the global ataxia market include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan

Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be classified into three types on the basis of cause: acquired ataxia, genetic ataxia, and idiopathic ataxia. Acquired ataxia is caused by external factors such as vitamin deficiencies, head trauma, microbial infection, brain tumor, and exposure to drugs or alcohol. Genetic ataxia is caused when a damaged gene which leads to ataxia is passed from one generation to the other. Idiopathic ataxia is a condition wherein the cause is unknown. Few of the symptoms associated with ataxia include decreasing coordination, trouble in walking, impaired balance with frequent falls, loss of fine motor skills, muscle tremors, slurred speech, vision problems, and others. Ataxia can develop at any age and is progressive in nature i.e. it worsens with time.

Market Dynamics

The increasing incidence of ataxia, rising research and development activities for the development of novel therapeutics for the treatment of ataxia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global ataxia market over the forecast period.

For instance, according to an article published by the Clinical and Translational Neuroscience journal, in August 2018, it is estimated that the global occurrence rate of ataxia is 26/100,000 in children wherein the occurrence rate for dominant hereditary cerebellar ataxia is 2.7/100,000 and the occurrence rate for recessive hereditary cerebellar ataxia 3.3/100,000, as of 2018.

Key features of the study:

  • This report provides in-depth analysis of the global ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global ataxia market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global ataxia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ataxia market

Detailed Segmentation:

  • Global Ataxia Market, By Treatment Type:
    • Pharmacotherapy
      • Levodopa
      • Pramipexole
      • Desvenlafaxine
      • Venlafaxine
      • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
    • Physical Therapy
    • Speech Therapy
    • Others (Adaptive Devices and Occupational Therapy)
  • Global Ataxia Market, By Disease Type:
    • Friedreich's Ataxia
    • Ataxia-telangiectasia
    • Spinocerebellar Ataxias
    • Episodic Ataxia
    • Others (Multiple System Atrophy (MSA))
  • Global Ataxia Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Ataxia Market, By Region:
    • North America
      • By Treatment Type
        • Pharmacotherapy
          • Levodopa
          • Pramipexole
          • Desvenlafaxine
          • Venlafaxine
          • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
        • Physical Therapy
        • Speech Therapy
        • Others (Adaptive Devices and Occupational Therapy)
      • By Disease Type
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Treatment Type
        • Pharmacotherapy
          • Levodopa
          • Pramipexole
          • Desvenlafaxine
          • Venlafaxine
          • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
        • Physical Therapy
        • Speech Therapy
        • Others (Adaptive Devices and Occupational Therapy)
      • By Disease Type
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment Type
        • Pharmacotherapy
          • Levodopa
          • Pramipexole
          • Desvenlafaxine
          • Venlafaxine
          • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
        • Physical Therapy
        • Speech Therapy
        • Others (Adaptive Devices and Occupational Therapy)
      • By Disease Type
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type
        • Pharmacotherapy
          • Levodopa
          • Pramipexole
          • Desvenlafaxine
          • Venlafaxine
          • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
        • Physical Therapy
        • Speech Therapy
        • Others (Adaptive Devices and Occupational Therapy)
      • By Disease Type
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment Type
        • Pharmacotherapy
          • Levodopa
          • Pramipexole
          • Desvenlafaxine
          • Venlafaxine
          • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
        • Physical Therapy
        • Speech Therapy
        • Others (Adaptive Devices and Occupational Therapy)
      • By Disease Type
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type
        • Pharmacotherapy
          • Levodopa
          • Pramipexole
          • Desvenlafaxine
          • Venlafaxine
          • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
        • Physical Therapy
        • Speech Therapy
        • Others (Adaptive Devices and Occupational Therapy)
      • By Disease Type
        • Antimetabolite
        • Kinase Inhibitors
        • Alpha Interferon
        • Selective Serotonin Reuptake Inhibitors
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • CRISPR Therapeutics
    • Acorda Therapeutics
    • Capsida Biotherapeutics Inc.
    • Larimar Therapeutics, Inc.
    • Healx
    • Intellia Therapeutics, Inc.
    • Editas Medicine
    • bluebird bio, Inc.
    • Sanofi
    • Merck & Co., Inc.
    • H. Lundbeck A/S
    • Cellectis SA
    • Bio-Techne
    • GlaxoSmithKline plc
    • Allergan

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Highlights
    • Reimbursement Scenario
    • Mergers & Acquisitions
  4. Global Ataxia Market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Ataxia Market, By Treatment Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Pharmacotherapy
      • Levodopa
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Pramipexole
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Desvenlafaxine
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Venlafaxine
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Physical Therapy
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Speech Therapy
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Others (Adaptive Devices and Occupational Therapy)
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Ataxia Market, By Disease Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Friedreich's Ataxia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Ataxia-telangiectasia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Spinocerebellar Ataxias
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Episodic Ataxia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others (Multiple System Atrophy (MSA))
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Ataxia Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  8. Global Ataxia Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CRISPR Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Acorda Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Capsida Biotherapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Larimar Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Healx
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Intellia Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Editas Medicine
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • bluebird bio, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • H. Lundbeck A/S
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cellectis SA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bio-Techne
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Allergan
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 33 market data tables and 25 figures on "Ataxia Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global ataxia market size is estimated to be valued at US$ 30,880.5 million in 2021 and is expected to exhibit a CAGR of 9.4% between 2021 and 2028.
Increasing incidence of ataxia and increasing research and development activities for the development of novel therapeutics for the treatment of ataxia are expected to drive the market growth over the forecast period.
Pharmacotherapy segment is expected to hold the major market share, owing to market players focusing on obtaining regulatory approvals for new drugs used in treatment of ataxia during the forecast period.
North America holds the largest market share in the market.
Major factors hampering growth of the market include rarity of ataxia diseases which cause a hurdle in conducting clinical trials.
Major players operating in the market include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.